Pharmafile Logo
Pharmafocus logo
Advanced Search

Neurology

Showing 15 posts of 116 posts found.

Neurizon confirms positive results for prospective ALS treatment

June 23, 2025
Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases

Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …

News

Roche advances treatment for Parkinson’s disease

June 16, 2025
Research and Development Neurology, Parkinson's disease, Roche, clinical trials, neurodegenerative disease

Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, an investigational therapy for Parkinson’s …

News
handshake

Chiesi partners with Key2Brain to develop therapies for rare neurodegenerative diseases

June 12, 2025
Manufacturing and Production, Mergers and Acquisitions, Research and Development Chiesi Group, Key2Brain, Neurology, Rare Diseases, lysosomal storage disorders, neurodegenerative disease, partnership, ultra-rare disease

Italian biopharma, Chiesi Group, and Key2Brain, a Swedish biotech, have agreed to advance the development of two blood-brain barrier (BBB)-crossing …

News

Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research

June 10, 2025
Conferencing, Events & Incentives, Interactive Conferences, Medical Communications, Research and Development, Sales and Marketing Guillain-Barré syndrome, Hansa Biopharma, Immunology, Neurology, investor event

Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 June 2025. The webcast aims …

News
hsm_mobile_clinical_trial_istock-872676342

Corcept reports survival benefit in ALS trial of dazucorilant despite missing primary endpoint

June 9, 2025
Research and Development Corcept Therapeutics, European Network to Cure ALS (ENCALS), Neurology, amyotrophic lateral sclerosis, clinical trial

Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients with amyotrophic lateral sclerosis (ALS), …

News

Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy

June 5, 2025
Research and Development European Commission, Evrysdi, Neurology, Roche, european union, neuromuscular condition, spinal muscular atrophy (SMA)

Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and …

News
lab

Study links COVID-19 and some vaccines to increased risk of rare neurological condition

June 5, 2025
Medical Communications, Medical Education, Medical/ Scientific Writing, Research and Development COVID-19, COVID-19 vaccine, Guillain-Barré Syndrome (GBS), Neurology, Virology, adenoviral vector vaccines, mRNA-based vaccines, medical study, neurological condition

An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral …

News
handshake

Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline

May 23, 2025
Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …

News

Galimedix completes key stage of clinical trial for treatment targeting eye and brain diseases

May 9, 2025
Research and Development Galimedix Therapeutics, Neurology, Opthalmology, R&D, clinical trial, neurodegenerative conditions

Clinical biotech, Galimedix Therapeutics, has announced the completion of a single ascending dose (SAD) part of a phase 1 study …

News
clinical_trials

Successful clinical outcomes for drug treating rare stroke condition

April 25, 2025
Research and Development Bioxodes, Neurology, clinical trial, stroke

Flemish biopharma company, Bioxodes, has announced promising results from the BIRCH phase 2a clinical trial of BIOX-101 to treat intracerebral …

News

Neurizon makes appointments to executive team

April 24, 2025
Recruitment, Senior Management Neurizon, Neurology, als, biotech, neurodegenerative diseases

Neurizon Therapeutics, a clinical-stage biotech company focusing on treatments for neurodegenerative diseases, has announced three leadership appointments. These will support …

Appointment

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

April 10, 2025
Research and Development Alzheimer's disease, Neurology, TauRx Pharmaceutics, research and development

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the progression of Alzheimer’s disease over …

News
biology-think-networking-physiology-brain-anatomy-2676370

ADHD coach and breathwork experts to run workshop for ADHD management

April 2, 2025
Design & Creative, Freelancers ADHD, Neurology, healthcare, mental health, nervous system

ADHD coach John Harrington and breathwork facilitator Martin O’Toole will collaborate on ‘Breathwork for ADHD and Beyond’, a breathwork-orientated session …

News

University of Southern Denmark pairs with Argobio to launch next-generation RNA company Inverna Therapeutics

January 7, 2025
Research and Development Argobio, Huntingdon's Disease, Inverna therapeutics, Neurology, RNA therapeutics, University of Southern Denmark ], gene splicing

The launch of new RNA company Inverna Therapeutics was announced today. Inerva Therapeutics begins with a programme aimed at transforming …

News

UCB presents epilepsy research at American Epilepsy Society Annual Meeting

December 9, 2024
Research and Development American Epilepsy Society, Dravet Syndrome, Neurology, UCB, sleep

Belgian-based biopharmaceutical company UCB has announced it will present 32 abstracts at the American Epilepsy Society (AES) Annual Meeting – …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026